We are live on
!
Find out more
PIM
Partner Investment Management Portfolio holdings
AUM
$13.9M
1-Year Est. Return
55.92%
This Fund
S&P 500
This Quarter
Est. Return
+10.06%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$31.3M
(+34%)
Cap. Flow
+$17.7M
Cap. Flow
% of AUM
14.26%
Top 10 Holdings %
Top 10 Hldgs %
30.99%
Holding
124
New
34
Increased
26
Reduced
39
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBX
Unity Biotechnology
UBX
|
+$4.51M |
| 2 |
Spotify
SPOT
|
+$1.47M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.31M |
| 4 |
Centene
CNC
|
+$1.21M |
| 5 |
APTX
Aptinyx Inc. Common Stock
APTX
|
+$1.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALNA
Allena Pharmaceuticals
ALNA
|
+$4M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$3.52M |
| 3 |
Microsoft
MSFT
|
+$2.51M |
| 4 |
Baxter International
BAX
|
+$1.81M |
| 5 |
Box
BOX
|
+$1.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.55% |
| 2 | Technology | 12.71% |
| 3 | Communication Services | 9.85% |
| 4 | Consumer Discretionary | 3.5% |
| 5 | Financials | 2.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
101
DELISTED
bluebird bio
BLUE
| – | – |
-135
| Closed | -$298K |
|
|
102
CALL
Bristol-Myers Squibb
BMY
$131B
| – | – |
-26,000
| Closed | -$1.65M |
|
|
103
Bristol-Myers Squibb
BMY
$131B
| – | – |
-55,719
| Closed | -$3.52M |
|
104
DexCom
DXCM
$31.3B
| – | – |
-31,728
| Closed | -$588K |
|
105
Inogen
INGN
$176M
| – | – |
-20
| Closed | -$2K |
|
|
106
Microsoft
MSFT
$3.71T
| – | – |
-27,467
| Closed | -$2.51M |
|
107
Regenxbio
RGNX
$745M
| – | – |
-8,856
| Closed | -$264K |
|
108
LendingTree
TREE
$447M
| – | – |
-1,349
| Closed | -$443K |
|
109
Tesla
TSLA
$1.26T
| – | – |
-28,530
| Closed | -$506K |
|
110
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.19B
| – | – |
-15,100
| Closed | -$1.32M |
|
|
SYNH
111
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| – | – |
-7,623
| Closed | -$271K |
|
|
JNCE
112
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-14,916
| Closed | -$333K |
|
|
GBT
113
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-946
| Closed | -$46K |
|
|
PTLA
114
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-7,200
| Closed | -$235K |
|
Similar funds
SWM
ACM
ECAU
SL
DII
FIM
EM
BHC
Partner Investment Management's Q2 2018 Portfolio in Review
As of Q2 2018, Partner Investment Management held 124 positions worth $124M, up 34% from $92.6M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Partner Investment Management deployed $17.7M of net new capital in Q2 2018, opening 34 new positions and adding to 26 existing holdings. Its largest new stake was Unity Biotechnology: 30,876 shares worth $4.08M.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 57% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Allena Pharmaceuticals, an estimated $4M trimmed.
- Partner Investment Management's largest Q2 2018 buy was Unity Biotechnology: 30,876 shares worth $4.08M.
- Partner Investment Management added most to Alphabet (Google) Class A in Q2 2018, an estimated $1.12M increase.
- Partner Investment Management's biggest Q2 2018 reduction was Allena Pharmaceuticals, cutting an estimated $4M.
- Partner Investment Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $3.52M.
- Partner Investment Management's ten largest holdings make up 31% of its $124M portfolio in Q2 2018.
- Partner Investment Management opened 34 new positions and closed 14 in Q2 2018.
- Partner Investment Management's portfolio value rose 34% quarter-over-quarter to $124M.
Based on Partner Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.